169 related articles for article (PubMed ID: 29137393)
1. Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Rao SS; Stoehr J; Dokic D; Wan L; Decker JT; Konopka K; Thomas AL; Wu J; Kaklamani VG; Shea LD; Jeruss JS
Oncotarget; 2017 Oct; 8(48):83925-83939. PubMed ID: 29137393
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Tarasewicz E; Rivas L; Hamdan R; Dokic D; Parimi V; Bernabe BP; Thomas A; Shea LD; Jeruss JS
Cell Cycle; 2014; 13(20):3191-201. PubMed ID: 25485498
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
5. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Rajput S; Guo Z; Li S; Ma CX
Oncotarget; 2019 Jun; 10(38):3667-3680. PubMed ID: 31217901
[TBL] [Abstract][Full Text] [Related]
6. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
[TBL] [Abstract][Full Text] [Related]
7. Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
Oba T; Ito KI
Oncotarget; 2018 May; 9(33):22986-23002. PubMed ID: 29796167
[TBL] [Abstract][Full Text] [Related]
8. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N; Evans KW; Akcakanat A; Yuca E; Tapia C; Rizvi YQ; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2019 Aug; 10(49):5011-5019. PubMed ID: 31489111
[No Abstract] [Full Text] [Related]
9. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.
Terashima M; Sakai K; Togashi Y; Hayashi H; De Velasco MA; Tsurutani J; Nishio K
Springerplus; 2014; 3():417. PubMed ID: 25140293
[TBL] [Abstract][Full Text] [Related]
10. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
[TBL] [Abstract][Full Text] [Related]
12. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
[TBL] [Abstract][Full Text] [Related]
13. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
14. Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.
Ko H; Lee M; Cha E; Sul J; Park J; Lee J
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454385
[No Abstract] [Full Text] [Related]
15. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
Xie X; Lee J; Fuson JA; Liu H; Iwase T; Yun K; Margain C; Tripathy D; Ueno NT
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979714
[TBL] [Abstract][Full Text] [Related]
16. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
18. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
19. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]